Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01621113 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury
A Phase 2 study, sponsored by Kessler Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01621113 is a Phase 2 study that has completed, run by Kessler Foundation. The registered enrollment target is 27 participants.
The verdict
NCT01621113, a Phase 2 study, has completed, sponsored by Kessler Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy, safety, and tolerability of treatment with dalfampridine in combination with locomotor training in persons with chronic, motor incomplete SCI.
Interventions
- DRUG Placebo
- DRUG Dalfampridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01621113
The ClinicalTrials.gov registry entry for NCT01621113 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kessler Foundation, which has 104 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01621113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01621113 about?
NCT01621113 is a clinical study titled "Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury". The purpose of this study is to determine the efficacy, safety, and tolerability of treatment with dalfampridine in combination with locomotor training in persons with chronic, motor incomplete SCI.
What is the current status of trial NCT01621113?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2012-06. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT01621113?
The interventions under investigation include: Placebo (DRUG), Dalfampridine (DRUG).
Who is sponsoring clinical trial NCT01621113?
This trial is sponsored by Kessler Foundation, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.